Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Sees Return To Earnings Growth And "Turnaround" Phase On Horizon

This article was originally published in The Pink Sheet Daily

Executive Summary

Schering should enter the "turnaround" phase of the company's five-point "action agenda" later in 2005, after two or three quarters of solid performance, CEO Hassan says. Exec cautions progress to date is tenuous: Schering's small product base means a shift in market share for the Zetia/Vytorin franchise could have a big impact on bottom line.
Advertisement

Related Content

Schering-Plough Sets Acquisition Sights On Specialty Products
Schering-Plough Sets Acquisition Sights On Specialty Products
Merck Tallies Vytorin Switches: 27% From Zocor, 24% From Lipitor
Merck Tallies Vytorin Switches: 27% From Zocor, 24% From Lipitor

Topics

Advertisement
UsernamePublicRestriction

Register

PS062051

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel